Equinixin

Main information

  • Trade name:
  • Equinixin 2.5% w/w Granules for Horses
  • Pharmaceutical form:
  • Granules for oral solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Equinixin 2.5% w/w Granules for Horses
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • flunixin
  • Therapeutic area:
  • Horses

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0374/001
  • Authorization date:
  • 23-08-2011
  • EU code:
  • UK/V/0374/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:August2011

AN:00483/2011

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Equinixin25mg/gGranulesforHorses(UK)

Flunixin25mg/gGranulesforHorses

FlunixineGranules25mg/gforHorses(FR)

Flunixinvet25mg/gGranulesforHorses(FI)

Flunimeg250mgGranulesforHorses(DK)

FlunixinN-vet25mg/gGranulesforHorses(SE)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Each10gsachetcontains:

ActiveSubstance

Flunixin 250mg

(asflunixinmeglumine)

Excipients

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Granules.

Whitetocreamcolouredgranules

4. CLINICALPARTICULARS

4.1Targetspecies

Horses

4.2Indicationsforuse,specifyingthetargetspecies

Forthealleviationofinflammationandpainassociatedwithmusculo-skeletal

disorders

4.3Contraindications

Donotuseinanimalssufferingfromcardiac,hepaticorrenaldisease,wherethereis

thepossibilityofgastrointestinalulcerationorbleeding,wherethereisevidenceofa

blooddyscrasiaorhypersensitivitytotheproduct

4.4Specialwarningsforeachtargetspecies

None.

Revised:August2011

AN:00483/2011

4.5Specialprecautionsforuse

i. SpecialPrecautionsforuseinanimals:

Donotexceedtherecommendeddoseorthedurationoftreatment.

Useinanyanimallessthan6weeksofageorinagedanimalsmayinvolve

additionalrisk.

Ifsuchusecannotbeavoidedanimalsmayrequireareduceddosageand

carefulclinicalmanagement.

Avoiduseinanydehydrated,hypovolaemicorhypotensiveanimalasthereisa

potentialriskofincreasedrenaltoxicity.

ii.Specialprecautionstobetakenbythepersonadministeringtheproducttothe

animals:

Avoidinhalation,contactwitheyesanddirectcontactwithskin.

Incaseofspillageontoskinwashimmediatelywithwater.

Inthecaseofaccidentalcontactwitheyes,rinseimmediatelywithplentyof

waterandseekmedicaladvice.

Toavoidpossiblesensitisationreactions,avoidcontactwiththeskin.Gloves

shouldbewornduringapplication.Washhandsafteruse.

Theproductmaycausereactionsinsensitiveindividuals.Ifyouhaveknown

hypersensitivityfornon-steroidalanti-inflammatoryproductsdonothandlethe

product.Reactionsmaybeserious.

4.6Adversereactions(frequencyandseriousness)

Untowardeffectsincludegastrointestinalirritation,ulcerationand,indehydratedor

hypovolaemicanimals,potentialforrenaldamage.Ifadversereactionsoccur,

treatmentshouldbediscontinuedandtheadviceofaveterinarianshouldbesought.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoriesanimalshaveshownevidenceoffoetotoxiceffectsofthe

flunixinafteroraladministration(rabbitandrat)andintramuscularadministration(rat)

atmaternotoxicdosesaswellasanincreaseinthegestationperiod.Studiesto

demonstratesafetyinpregnantmareshavenotbeenconducted.Donotadminister

theproducttopregnantmares.

4.8Interactionswithothermedicinalproductsandotherformsofinteraction

Donotadministerothernon-steroidalanti-inflammatorydrugs(NSAID)or

glucocorticosteroidsconcurrently,orwithinatleast24hoursofadministrationofthis

product.Thetreatment-freeperiodshouldtakeintoaccountthepharmacokinetic

propertiesoftheproductsused.Concurrentuseofotheractivesubstancesthathave

ahighdegreeofproteinbindingmaycompetewiththisproduct,whichmayleadto

toxiceffects.

Gastrointestinaltractulcerationmaybeexacerbatedbycorticosteriodsinpatients

givenNSAIDs.

Concurrentadministrationofpotentiallynephrotoxicdrugsshouldbeavoided.

ItispreferablethatNSAID’swhichinhibitprostaglandinsynthesisarenot

administeredtoanimalsundergoinggeneralanaesthesiauntilfullyrecovered.

Revised:August2011

AN:00483/2011

4.9Amounttobeadministeredandadministrationroute

Fororaladministrationonly.

Thedoserateis1.1mgflunixinperkgbodyweighti.e.one10gsachetper227kg

(500lb)bodyweightoncedailyforupto5consecutivedaysaccordingtoclinical

response.

Thisproductisadministeredbysprinklingonasmallamountoffood.Addtofeed

immediatelybeforeadministration.Discardanyremainingmedicatedfeed.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Flunixinmeglumineisanon-steroidalanti-inflammatorydrug.Overdosageis

associatedwithgastrointestinaltoxicity.

4.11Withdrawalperiods

Meatandoffal:15Days

Milk:Notpermittedforuseinlactatingmaresproducingmilkforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Non-steroidalanti-inflammatory

ATCvetCode:QM01AG90

5.1Pharmacodynamicproperties

Flunixinmeglumineisarelativelypotentnon-narcotic,non-steroidalanalgesicwith

anti-inflammatoryandanti-pyreticproperties.

Flunixinmeglumineactsasareversiblenon-selectiveinhibitorofcyclo-oxygenase

(bothCOX1andCOX2forms),animportantenzymeinthearachidonicacid

cascadepathwaywhichisresponsibleforconvertingarachidonicacidtocyclic

endoperoxides.Consequently,synthesisofeicosanoids,importantmediatorsofthe

inflammatoryprocessinvolvedincentralpyresis,painperceptionandtissue

inflammation,isinhibited.Throughitseffectsonthearachidonicacidcascade,

flunixinalsoinhibitstheproductionofthromboxane,apotentplateletpro-aggregator

andvasoconstrictorwhichisreleasedduringbloodclotting.Flunixinexertsits

antipyreticeffectbyinhibitingprostaglandinE2synthesisinthehypothalamus.

Althoughflunixinhasnodirecteffectonendotoxinsaftertheyhavebeenproduced,it

reducesprostaglandinproductionandhencereducesthemanyeffectsofthe

prostaglandincascade.Prostaglandinsarepartofthecomplexprocessesinvolvedin

thedevelopmentofendotoxicshock.

5.2Pharmacokineticproperties

AfterasingleadministrationofEquinixinGranulestohorsesat1.1mg/kgofflunixin,

maximumplasmaconcentrationofflunixin(2.51µg/ml)isreachedinabout1hour.

Revised:August2011

AN:00483/2011

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

PovidoneK30

Crospovidone

PregelatinisedStarch(Maize)

Lactosemonohydrate

Sucrose

PeppermintFlavour

CelluloseMicrocrystalline

6.2Incompatibilities

Noneknown

6.3Shelf-life

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelf-lifeafteradditiontofeed:Useimmediately

6.4Specialprecautionsforstorage

Donotstoreabove25

C.Keepthesachetintheoutercarton.

6.5Natureandcompositionofimmediatepackaging

Cartonsof10laminatedfoil(C1S/LDPE/Alu/SP)sachetseachcontaining10g

granules

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproducts

orwastematerialsderivedfromtheuseofsuchproducts,ifappropriate

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

NorbrookLaboratoriesLimited

StationWorks

CamloughRoad

NEWRY

Co.Down,BT356JP

NorthernIreland

8. MARKETINGAUTHORISATIONNUMBER

Vm 02000/4241

Revised:August2011

AN:00483/2011

9. DATEOFFIRSTAUTHORISATION

Date:9March2006

10.DATEOFREVISIONOFTHETEXT

Date:August2011

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

31-7-2018

Public Notification: Black Rhino 25000 contains hidden drug ingredient

Public Notification: Black Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Black Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Krazzy Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Gold Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Platinum Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

10-7-2018

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

PrEP wordt binnen een onderzoekssetting voor een periode van vijf jaar verstrekt aan de hoogrisicogroep van mannen die seks hebben met mannen (MSM). Dat heeft minister Bruno Bruins (Medische Zorg) vandaag bekend gemaakt. Op basis van schattingen van het RIVM zullen ongeveer 6500 mannen hiervan gebruik gaan maken en kunnen hiermee  250 hiv-infecties per jaar worden voorkomen. Voor gebruikers gaat een eigen bijdrage gelden van maximaal 25%, dat komt overeen met ongeveer 12 euro per maand. Ook wordt hen gev...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

4-5-2018

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals, LLC of Springville, Utah is recalling Green Suma, Red Suma, Green Hulu 2, and Red Hulu 2 kratom dietary supplements sold directly to consumers via the company website from January 1st, 2018 to April l 12th, 2018 in pouches of 250g, because it has the potential to be contaminated with Salmonella.

FDA - U.S. Food and Drug Administration

15-1-2014

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

On 20 December 2013 and on 10 January 2014, the Danish Health and Medicines Authority decided to revoke the section 39 authorisations for wholesale distribution and manufacturing of medicinal products with the authorisation IDs 25081 and 25082 granted to Singad Pharma ApS (company number 255894).

Danish Medicines Agency

28-11-2018

PHEBURANE (Eurocept International BV)

PHEBURANE (Eurocept International BV)

PHEBURANE (Active substance: Sodium Phenylbutyrate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8043 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2500/T/20

Europe -DG Health and Food Safety

30-10-2018

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Active substance: Phosphorothioate oligonucleotide targeted to transthyretin) - Transfer of orphan designation - Commission Decision (2018)7282 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/098/13/T/01

Europe -DG Health and Food Safety

29-10-2018

Replagal (Shire Human Genetic Therapies AB)

Replagal (Shire Human Genetic Therapies AB)

Replagal (Active substance: Agalsidase alfa) - Centralised - Yearly update - Commission Decision (2018)7250 of Mon, 29 Oct 2018

Europe -DG Health and Food Safety

3-7-2018

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Active substance: tolvaptan) - Centralised - 2-Monthly update - Commission Decision (2018) 4250 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/980/II/31

Europe -DG Health and Food Safety

6-6-2018

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Active substance: efavirenz) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3689 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/250/T/113

Europe -DG Health and Food Safety

23-4-2018

Mylotarg (Pfizer Limited)

Mylotarg (Pfizer Limited)

Mylotarg (Active substance: gemtuzumab ozogamicin) - New authorisation - Commission Decision (2018)2504 of Mon, 23 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4204

Europe -DG Health and Food Safety